Learn more about our policy experts.

Media Contacts

Angela Bradbery, Director of Communications
w. (202) 588-7741
c. (202) 503-6768
abradbery@citizen.org, Twitter

Don Owens, Deputy Director of Communications
w. (202) 588-7767

Karilyn Gower, Press Officer
w. (202) 588-7779

David Rosen, Press Officer, Regulatory Affairs
w. (202) 588-7742

Other Important Links

Press Release Database
Citizen Vox blog
Texas Vox blog
Consumer Law and Policy blog
Energy Vox blog
Eyes on Trade blog

Follow us on Twitter


Sept. 30, 2015 At TPP Negotiations, U.S. Trade Rep Attempts to Resolve Pharmaceuticals Impasse by Wrapping Same Harmful Proposal in Different Packaging

Despite the Spin, Five Plus Three Still Equals Eight

ATLANTA – At the Trans-Pacific Partnership (TPP) negotiations in Atlanta, the U.S. Trade Representative (USTR) is pushing the same harmful pharmaceutical proposal that many countries have rejected as recently as August – but wrapped in different packaging.

The tactic is designed to break negotiators’ impasse over biotech drugs. The TPP talks in Maui collapsed a month ago when trade ministers sparred over several issues including biologics exclusivity. But the U.S. proposal would give pharmaceutical companies additional monopoly protections at the expense of public budgets and people’s health, Public Citizen said today.

The USTR has long pushed for increased marketing exclusivity periods for biologics – medical products derived from living organisms, including many new and forthcoming cancer treatments. Exclusivity means product monopolies, with no competition from generics or biosimilars; medicine prices in the tens and hundreds of thousands of dollars per person; and the rationing of treatment access. Marketing exclusivity is separate from and independent of patent protection, though the protections may overlap. The USTR has supported an eight-year minimum monopoly period, while a majority bloc of negotiating countries will not consider more than five years’ exclusivity.

The approach reportedly being explored by some negotiators would require a minimum five years marketing exclusivity followed by a three-year minimum period of post-marketing surveillance, which would also exclude competition through an unusual mechanism found in Japanese law. The approach would allow some countries to claim they are not changing their exclusivity laws or prior trade agreement deals on intellectual property and access to medicines, per public commitments those governments have made. But it would also allow the USTR to report to the pharmaceutical industry that they have secured eight-year biotech monopolies.

In other words, 5+3 = 8.

 “This is a cynical rebranding of a failed negotiating position,” said Peter Maybarduk, director of Public Citizen’s Global Access to Medicines program. “It represents the worst of secretive trade deals – a rule that has nothing to do with trade, but will lead to preventable suffering. You can put a suit and tie on this, but it still stinks. Non-U.S. TPP negotiators and trade ministers should continue standing strong against this USTR demand, because, despite the spin, five plus three still equals eight.”


Copyright © 2016 Public Citizen. Some rights reserved. Non-commercial use of text and images in which Public Citizen holds the copyright is permitted, with attribution, under the terms and conditions of a Creative Commons License. This Web site is shared by Public Citizen Inc. and Public Citizen Foundation. Learn More about the distinction between these two components of Public Citizen.

Public Citizen, Inc. and Public Citizen Foundation


You can support the fight for greater government and corporate accountability through a donation to either Public Citizen, Inc., or Public Citizen Foundation, Inc.

Public Citizen lobbies Congress and federal agencies to advance Public Citizen’s mission of advancing government and corporate accountability. When you make a contribution to Public Citizen, you become a member of Public Citizen, showing your support and entitling you to benefits such as Public Citizen News. Contributions to Public Citizen are not tax-deductible.

Public Citizen Foundation focuses on research, public education, and litigation in support of our mission. By law, the Foundation can engage in only very limited lobbying. Contributions to Public Citizen Foundation are tax-deductible.